Is anyone, anyone at all responsible in any way for any of this? Or is Starpharma just the unluckiest company to ever list on the ASX?
• Starpharma terminating the DEP-HER2 ADC program • Starpharma getting asked a for please explain by the MHRA in the UK and temporarily removing Viraleze from the shelves. • The lack of overall commercial success of Viraleze. • Viraleze failing to meet the primary endpoint of the Covid treatment trial. • The TGA refusing marketing approval for Viraleze. • The TGA fining Starpharma for alleged illegal advertising of Viraleze • The ASX asking Starpharma if one of their announcements constituted ramping. • The long-established research agreements not yet turning into licences. • BigPharma saying no thank you to licencing any of the internal DEP drugs for Phase 3 trials. • The extraordinarily delayed results of DEP-Docetaxel • The average Phase 2 trial results of DEP-Docetaxel • The subsequent de-prioritisation of the once flagship DEP-Docetaxel by Starpharma • DEP-Gemcitabine being withdrawn from going into clinical trials at the 11th hour. • The Sky and Land ‘deal’ for condoms in the Chinese Govt sector not going ahead. • Starpharma not commencing any new internal DEP trials since 2019 • The poor sales of VivaGel BV/Fleurstat • The poor performing partnership with Mundiparma that was subsequently terminated • AstraZeneca terminating the Phase One trial for solid cancers • AstraZeneca terminating the Phase One trial for non-hodgkin lymphoma • AstraZeneca terminating the Phase One trial for haematological malignancies • AstraZeneca not taking up the development and option agreement with Starpharma • Starpharma’s inability to get a BARDA grant for Viraleze in the USA • AstraZeneca deciding that Starpharma’s DEP platform no longer has any collaboration value • The Chase Sun anti-infective program being de-prioritised. • The proprietary condoms turning out to be a dud commercial product. • The once hyped but now shelved SPL7013 viral conjunctivitis opportunity • The non-eventuating Indian Viraleze deal • DEP-Remdesivir never seeing the light of day • The CRL issued to Starpharma by the FDA in 2018 • The subsequent long-running FDA legal saga • Starpharma ultimately failing in its formal dispute with the FDA • No broker coverage of Starpharma • Institutional investor capitulation • SPL being dumped from the ASX300 • SPL later being dumped from the All Ords Index • Starpharma’s glacial-paced early research and pre-clinical Radiopharmaceutical program
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)